TriSalus Life Sciences (TLSI) Net Income towards Common Stockholders (2021 - 2026)

TriSalus Life Sciences' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 113.88% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at -$58.5 million (down 92.95% YoY), while the FY2025 annual figure was -$69.7 million, down 109.7% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $1.5 million, up from -$9.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.3 million in Q1 2022, with the low at -$41.3 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$9.2 million (2023), against an average of -$11.5 million.
• Peak annual rise in Net Income towards Common Stockholders reached 2419.36% in 2022, while the deepest fall reached 4565.49% in 2022.
• TriSalus Life Sciences' Net Income towards Common Stockholders stood at -$25.4 million in 2022, then slumped by 43.62% to -$36.4 million in 2023, then jumped by 70.11% to -$10.9 million in 2024, then advanced by 10.45% to -$9.8 million in 2025, then surged by 115.78% to $1.5 million in 2026.
• Business Quant data shows TLSI's Net Income towards Common Stockholders at $1.5 million in Q1 2026, -$9.8 million in Q4 2025, and -$41.3 million in Q3 2025.